An analysis of almost 4,000 patients with breast cancer found that testing for high activity in a particular gene called alpha beta (aB)-crystallin could pick out women who were at greater risk of developing secondary brain tumors compared to women who tested negative.
A team including scientists at The Institute of Cancer Research, London, found that women whose breast cancer had begun to spread and who tested positive in the aB-crystallin test were three times more likely to have disease that spread to the brain than those who tested negative.
Help employers find you! Check out all the jobs and post your resume.
